TLR3 and lung carcinoma: In mice models of breast and lung cancers, TLR3 activation was reported to: (a) elicit chemoattraction of cytotoxic lymphocytes to the growing tumor [15, 19, 20], (b) induce secretion of type I interferon (IFN) and inflammatory cytokine/chemokine and (c) enhance anti-tumor immune responsiveness [16, 21].